namodenoson

After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint
Fierce Biotech
Wed, 03/27/19 - 11:34 pm
Can-Fite BioPharma
liver cancer
namodenoson
clinical trials